Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.

By Hollie J. Pegram, James C Lee, Erik Hayman, G. Imperato, T. Tedder, Michel Sadelain, R. Brentjens. 2012

651 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Interleukin 12: still a promising candidate for tumor immunotherapy? (2014, background): “Moreover, IL-12 has strengthened the antitumor activity of adoptive therapy with targeted T cells engineered to secrete IL-12 [104] or therapy with oncolytic Herpes simplex virus expressing IL-12 [105].”
Engineering strategies to overcome the current roadblocks in CAR T cell therapy (2019, background): “Subsequently, genetic modification of CAR T cells to express IL-12 resulted in increased cytotoxicity and resistance to T reg cell-mediated inhibition in vitro, better engraftment without preconditioning chemotherapy and enhanced anti-tumour activity in vivo 185 .”
The Principles of Engineering Immune Cells to Treat Cancer (2017, background): “TILs with engineered NFAT-inducible IL-12 have antitumor activity in melanoma and severe toxicity (Zhang et al., 2015).”
TRUCKs: the fourth generation of CARs (2015, methodology): “In a pre-clinical model of CD19 lymphoma, T cells with inducible IL-12 eradicated established disease; the anti-tumor activity required both CD4 and CD8 T cells, IFN-g release and autocrine acting IL-12 [31].”